MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Tricida Operativer Cashflow 2011-2026 | TCDA
Operativer Cashflow Jährlich Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -140 M | -231 M | -130 M | -94.9 M | -40.4 M | -23.1 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -23.1 M | -231 M | -110 M |
Operativer Cashflow Vierteljährlich Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -70.7 M | -52 M | -26.4 M | - | -102 M | -73.1 M | -31 M | - | -189 M | -129 M | -51 M | - | -99.9 M | -56.9 M | -23.8 M | - | -62 M | -34.1 M | -15.1 M | - | -24.5 M | -16.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -15.1 M | -189 M | -62.1 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.18 | 1.92 % | $ 44.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.68 | -0.7 % | $ 2.07 B | Canada |
 |
Harrow Health
HROW
|
43.9 M | $ 37.94 | 2.27 % | $ 1.39 B | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.53 | 1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.09 | 0.93 % | $ 117 M | Canada |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.43 | 0.7 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.44 | 5.11 % | $ 3.37 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
-42.3 M | $ 4.44 | 2.54 % | $ 286 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 8.66 | 5.1 % | $ 443 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 6.91 | 2.83 % | $ 4.27 B | Canada |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.51 | 5.46 % | $ 330 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.75 | -1.29 % | $ 1.1 B | USA |
 |
Veru
VERU
|
-21.7 M | $ 2.42 | 1.68 % | $ 326 M | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Viatris
VTRS
|
2.9 B | $ 13.91 | 0.58 % | $ 16.7 B | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-353 K | $ 0.73 | -2.28 % | $ 3.15 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 7.19 | -2.57 % | $ 284 M | USA |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 1.02 | 0.99 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 8.23 | -1.91 % | $ 720 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.18 | -7.23 % | $ 2.71 M | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 0.93 | -1.38 % | $ 33.5 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.11 | 2.93 % | $ 24.4 M | USA |